Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus

Campos-Balea, Begoña; Fernández-Calvo, O.; García‐Figueiras, Roberto; Neira, Carlos; Peña-Penabad, Carmen; Rodríguez-López, Carmela; Vílchez-Simo, Rocío; Quindós-Varela, María

doi:10.1007/s12094-022-02822-x

Cited by 4 publications

(4 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early recognition of tumor relapse, when the patient is still asymptomatic, allows us to treat the lesion more conservatively, trying to achieve the oncologic radicality but, at the same time, limit the cosmetic impact, particularly in cases of less aggressive tumors such as BCCs located in highly aesthetic areas such as the face. In the field of CM, the introduction of targeted immunotherapies, also in the adjuvant setting, has made early detection of recurrence a key issue 24 …”

Section: Discussionmentioning

confidence: 99%

“…In the field of CM, the introduction of targeted immunotherapies, also in the adjuvant setting, has made early detection of recurrence a key issue. 24…”

Section: Discussionmentioning

confidence: 99%

“…Local tumor recurrence can be visible at inspection or palpable. In this case, it will be detected by the patient, incidentally or during regular self‐palpation, or by the referring physician at periodic follow‐ups 2,24 . In other circumstances, when the tumor relapse is not visible or palpable, only imaging modalities such as ultrasound will be able to demonstrate it.…”

Section: Introductionmentioning

confidence: 99%

“…In this case, it will be detected by the patient, incidentally or during regular self-palpation, or by the referring physician at periodic followups. 2,24 In other circumstances, when the tumor relapse is not visible or palpable, only imaging modalities such as ultrasound will be able to demonstrate it. In BCC local recurrences are also possible in case of topical, nonsurgical treatment.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Ultrasound Assessment of Skin Tumors Local Recurrence

Catalano

Crişan²,

Díaz

et al. 2023

J of Ultrasound Medicine

View full text Add to dashboard Cite

Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonmelanoma malignancies can be managed efficaciously, with a relevant impact on morbidity and survival. Ultrasound is being employed with increasing frequency in the assessment of skin tumors, but most of the published articles relate to initial pretherapeutic diagnosis and staging. This review aims to offer an illustrated guide to the sonographic evaluation of locally recurring skin cancer. We introduce the topic, then we provide some sonographic tips for patient follow‐up, then we describe the ultrasound findings in case of local recurrence, illustrating the main mimickers, and finally, we mention the role of ultrasound in guiding diagnostic and therapeutic percutaneous procedures.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the field of CM, the introduction of targeted immunotherapies, also in the adjuvant setting, has made early detection of recurrence a key issue. 24…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Ultrasound Assessment of Skin Tumors Local Recurrence

Catalano

Crişan²,

Díaz

et al. 2023

J of Ultrasound Medicine

View full text Add to dashboard Cite

show abstract

SEOM-GEM clinical guidelines for cutaneous melanoma (2023)

Márquez-Rodas,

Muñoz Couselo,

Rodríguez Moreno

et al. 2024

Clin Transl Oncol

View full text Add to dashboard Cite

Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant—and more recently neoadjuvant—with targeted therapy—BRAF and MEK inhibitors—and immunotherapy—anti-PD-1-based therapies—offer opportunities to reduce the risk of relapse and distant metastases. For patients with advanced disease not amenable to radical treatment, these treatments offer an unprecedented increase in overall survival. A group of medical oncologists from the Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines, based on a thorough review of the best evidence available. The following guidelines try to cover all the aspects from the diagnosis—clinical, pathological, and molecular—staging, risk stratification, adjuvant therapy, advanced disease therapy, and survivor follow-up, including special situations, such as brain metastases, refractory disease, and treatment sequencing. We aim help clinicians in the decision-making process.

show abstract